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Alzheimer disease (AD) is the most common form of 
dementia, aﬀ  ecting 5.5 million people in the US. Pro-
gressive neurodegeneration results in relentless cognitive 
decline, posing a substantial public health burden, and 
has major implications at the individual level. AD pheno-
types are divided into early-onset (EOAD) and late-onset 
(LOAD) AD with the arbitrary cutoﬀ   of 65 years in most 
studies [1].
Approximately 1% to 6% of all AD is early-onset. 
Genetics plays a more signiﬁ  cant role in EOAD, as this 
subset is enriched for familial disease in 60% of the cases 
[2]. Furthermore, 13% of EOAD has an autosomal domi-
nant inheritance pattern, and three genes – the amyloid 
precursor protein (APP), presenilin 1 (PSEN1), and 
presenilin 2 (PSEN2) – have been identiﬁ  ed as having 
mutations that cause EOAD. Th  ese genes contribute to 
approximately 80% of the autosomal dominant EOAD 
cases [2-4]. Although these mutations are rare and aﬀ  ect 
a small percentage of AD cases, the discovery of these 
three genes gave molecular genetic evidence supporting 
the amyloid hypothesis. As the amyloid cascade is the 
leading hypothesis, this cohort would be ideal for proof-
of-principle studies in amyloid-based drug therapy. 
However, their low prevalence and geographic dispersion 
make any trial exclusively with familial AD patients 
logistically challenging. Th  e organization of the Domi-
nantly Inherited Alzheimer Network [5] has been a major 
accomplishment in creating the logistic basis of such 
clinical trials, although owing to the small sample size, it 
is not likely that all drugs can be tested in this speciﬁ  c 
population.
On clinical grounds, EOAD and LOAD are distin-
guished on the basis of age of onset (AOO) alone. Several 
studies attempted to delineate the clinical, neuropsycho-
logical, imaging, pathological, and biomarker diﬀ  erences 
between EOAD and LOAD based on the 65-year 
arbitrary cutoﬀ   proposed by Amaducci and colleagues [1] 
in 1986. Th  e age of disease onset of patients with AD 
ranged from 50 to 99 in most studies but included 
subjects with AOO as low as 41 years in a few. As AOO is 
an estimate, the attempt to dichotomize the AOO 
distribution introduces both misclassiﬁ  cation of subjects 
around the cutoﬀ   and noise into the datasets. Further-
more, diverse onset ages within genetically deﬁ  ned 
families demonstrated that, even with the same upstream 
trigger, AOO can vary, suggesting that other genetic and 
environmental factors contribute to the AOO phenotype 
[6]. In addition, in vivo diagnosis of AD is estimated at 
95% accuracy, and therefore introduces noise due to 
some misclassiﬁ   cation bias [7]. After consideration of 
these limitations, there have been few replicable clinical 
diﬀ  erences between the EOAD and LOAD groups.
Diﬀ   erences in the neuropsychological proﬁ  les  are 
contro  versial and inconsistent between studies. While 
there is a consensus that LOAD appears to have a more 
predominant impairment of memory (with verbal 
memory aﬀ  ected more severely than nonverbal memory 
in general [8]), it remains unclear whether language, 
visuo  spatial abilities, and praxis are more aﬀ  ected  or 
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© 2011 BioMed Central Ltdpreserved in EOAD compared with LOAD [9]. Th  e 
literature suggested that language is more aﬀ  ected  in 
EOAD with preservation of visuospatial function [10,11], 
whereas more recently, praxis and visuospatial function 
appeared to be more aﬀ   ected when compared with 
LOAD [12]. Most research data support the hypothesis 
that there is greater involvement of the frontal-parietal 
structures in EOAD and more predominant deﬁ  cits in 
temporal lobe function with a propensity for the left 
hemisphere in LOAD [11,13,14].
Studies investigating the rate of disease progression by 
measuring cognitive and functional abilities over time 
yielded variable results. Some reports demonstrated that 
EOAD shows a more rapid progression [15-17], and 
others found that AOO is not a major predictor of the 
rate of progression [18,19].
Most voxel-based volumetric magnetic resonance 
imag  ing studies found that, in LOAD, hippocampal 
atrophy is prominent [20] whereas the pattern in EOAD 
is more variable. In EOAD, instances of atrophy of the 
temporal-parietal [21], parietal-occipital [20], temporal 
and posterior cingulate [22], and precuneus [23] areas 
have been reported. Th   e variability is likely due to study 
design, especially the selection of controls. Although 
there is some agreement that EOAD initially aﬀ  ects 
mainly the parietal associative cortex and LOAD aﬀ  ects 
the hippocampus, there are signiﬁ   cant variability and 
overlap between the two groups.
Evidence from brain metabolism studies suggests that 
EOAD is associated with changes that are more extensive, 
and studies most commonly report involvement of the 
precuneus and occipital cortex [24-26], and one study 
reports extension to the frontal cortex and subcortical 
grey matter [26]. Recent data indicate that regional or 
global [11C]-labelled Pittsburgh com  pound B binding is 
similar in early-onset and late-onset patients. In contrast, 
early-onset patients exhibit glucose metabolism that is 
signiﬁ   cantly lower than that of late-onset patients in 
precuneus/posterior cingulate, lateral temporo-parietal, 
and occipital corticies [27]. Th  e auto  somal dominant 
subset of EOAD demonstrates early uptake of Pittsburgh 
compound B in the caudate and the putamen [28,29]. 
Amyloid positron emission tomography studies using 
cerebellar uptake as reference may be confounded 
because of increased cerebellar uptake in the autosomal 
dominant subset.
Studies comparing biomarkers in the cerebrospinal 
ﬂ   uid in EOAD and LOAD demonstrated that beta-
amyloid(1-42) level is signiﬁ  cantly lower in EOAD as com-
pared with LOAD, with high sensitivity in both groups as 
a diagnostic marker [30].
Pathological studies demonstrated that the pathological 
hallmarks of AD and their regional distribution are 
similar [31]; however, quantitatively, a higher number of 
neuritic plaques and neuroﬁ  brillary tangles were found 
for the same severity of dementia in the EOAD group 
[32-34]. Th  e autosomal dominant subset of EOAD 
demon  strates gene- and mutation-speciﬁ  c diﬀ  erences in 
small case series, although all mutations are associated 
with the typical AD pathology and fulﬁ  ll the diagnostic 
criteria of the Consortium to Establish a Registry for 
Alzheimer’s Disease [35,36].
Th   e above-reviewed literature suggests that EOAD and 
LOAD are not likely to be fundamentally diﬀ  erent, as 
clinical, imaging, pathological, and biomarker data over-
lap and various studies have shown variable results; the 
data rather suggest heterogeneity of AD. Hetero  genenity 
decreases power, and thus one important question is 
whether including EOAD cases in clinical trials would 
add to heterogeneity and work against the ability to 
demonstrate drug-placebo diﬀ  erences.  Th  e  greatest 
accumu  lation of data on disease heterogeneity in AD 
involving large cohorts (thousands of cases) exists in 
genetic datasets. As AD has high heritability, it is 
legitimate to look at genetic heterogeneity of AD since 
tools are available to study this question and multiple 
well-designed studies have been reported. Th  e  genome-
wide association studies were early to point out the 
genetic heterogeneity of AD, showing that each locus has 
a low attributable risk manifesting in small odds ratios 
[37-39]. In the comparison of EOAD and LOAD, one of 
the major diﬀ   erences is in the genetic heterogeneity 
between the two groups. In EOAD, the heritability is 
higher and culprit genes have been identiﬁ  ed. Mutations 
in three genes account for 11% of the genetic causes, and 
this genetic load is markedly higher than that of the 
susceptibility genes in LOAD. In LOAD, causative genes 
have not been identiﬁ  ed, and the strongest risk allele is 
the APOE4 (apolipoprotein E) allele, conferring in the 
Caucasian population odds ratios of 10 to 14 in 
homozygotes and around 3 in heterozygotes [40]. 
Furthermore, incorporating EOAD cases may intro  duce 
subjects with mutations in APP, PSEN1, and PSEN2. As 
most animal models for AD involve mutations in one or a 
combination of these genes [41], preclinical testing is 
performed on transgenic animals that in fact model the 
pathomechanism responsible for AD in this subset of 
patients. Th   is group would be the ideal cohort for proof-
of-principle studies for amyloid targeted therapies, but 
this is unfortunately precluded by the rarity of mutation 
carriers. On the other hand, there is no compelling 
argument in favor of excluding genetic cases, even from 
trials assessing the eﬃ     cacy of therapies with a non-
amyloid target.
Clinical trial design is regulated and guidelines for the 
design of clinical trials for AD were published by the 
European Medicines Agency (EMEA) [42] and draft 
guidelines are available in the US and other countries. 
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AD as an exclusion criterion. Th  us, from a regulatory 
point of view, there is no reason not to include these 
patients. Th  e age range for current clinical trials is 
variable, with age 55, 60, or 65 years often used as the 
lower limit cutoﬀ   for enrollment. As the deﬁ  nition of 
EOAD is onset at less than 65 years of age, EOAD cases 
are already enrolled into clinical trials. Th   e EOAD subset 
that is currently excluded likely represents less than 1% of 
all AD cases and includes the majority of the autosomal 
dominant cases. Th   e conundrum is that we use transgenic 
animal models based on the amyloid hypothesis to test 
compounds for eﬃ   cacy, and subsequently we exclude the 
patients whose pathomechanism is closest to the model 
organism, in which it is most likely that the observed 
eﬀ  ect is replicated. Furthermore, if this 1% were to enroll 
in clinical trials, they would be randomly assigned, like all 
patients, to drug or placebo and could not substantially 
alter the outcome of the trial, even if they had a 
diﬀ  erential response to the treatment. Concerns about a 
diﬀ  erential safety proﬁ  le in autosomal dominant EOAD 
have been raised. As the validity of these concerns are 
uncertain, safety related to genetic status should be 
managed in trial design by addressing it in the monitoring 
procedure and subgroup analysis for the EOAD subset.
Finally, careful consideration of the ethical aspects of 
exclusion of EOAD patients is warranted. Although the 
fact is not formally stated, clinical trials exclude EOAD 
subjects in practice without justiﬁ  cation through their 
inclusion and exclusion criteria. Ethical guidelines stress 
the importance of considering access to outcomes of 
research [43] and have established the orphan drug 
category. Th   e category for orphan drug applies if a drug is 
intended for the diagnosis, prevention, or treatment of a 
life-threatening or chroni  cally debilitating condition that 
aﬀ   ects no more than 5 in 10,000 in the European 
Community and a disease that aﬀ  ects fewer than 200,000 
individuals in the US (according to the Orphan Drug Act) 
[44]. Th   e EOAD group is estimated to account for 1% to 
6% of subjects with AD, and EOAD aﬀ  ects 40,000 to 
200,000 individuals in the US or 1.2 to 7.4 in 10,000 
individuals in the European Community given an 
estimated AD prevalence of 1 in 68 people. EOAD cases 
excluded from clinical trials on the basis of the age 
criterion likely amount to fewer than 200,000 in the US 
or fewer than 5 in 10,000. Th  e EOFAD (early-onset 
familial Alzheimer disease) sub  group prevalence is fewer 
than 1 in 10,000, clearly fulﬁ  lling the orphan category 
criteria. A number of industrialized countries have 
passed speciﬁ   c legislation deﬁ  ning  epidemiological 
criteria for the designation of orphan status and 
consequent incentives to counteract the neglect of 
orphan disease in industrial research [45]. While 
distribution of resources is a major consideration, many 
would uphold that society has a moral obligation not to 
abandon individuals who had the bad luck to be aﬀ  ected 
by a serious but rare condition for which additional 
treatments are needed. In addition, medical investigators 
a professional obligation to advance scien  tiﬁ  c knowledge. 
AD represents a category in which drug development is 
active, but the orphan subset is excluded from research 
when these patients in fact might beneﬁ   t the most, 
especially from disease-modifying or preventive therapy.
Of the four biomedical ethics principles developed by 
Beauchamp and Childress [46] – autonomy, non-
maleﬁ  cence, beneﬁ  cence, and justice – the principles of 
autonomy, beneﬁ  cence, and justice are all relevant for the 
orphan diseases and for the subset of EOAD cases not 
currently included in trials. First, autonomy of EOAD 
subjects is compromised if they wish to contribute to 
research and are excluded from doing so without 
justiﬁ  cation, and this is the current practice. Second, in 
regard to the principle of justice, EOAD subjects should 
have access to and the opportunity to participate in 
research, and a rights-based approach could further sup-
port this claim. Even though the rights-based approach is 
underrepresented in the literature, its importance is 
implicit. Th  ird, Landman and Henley [47] proposed a 
basic moral commitment to non-abandonment which 
would clearly apply to these young and genetically 
aﬄ   icted individuals who suﬀ  er from AD.
Finally, we would like to compare and contrast two 
ethical theories that conﬂ  ict in the dilemma of what to do 
about EOAD subjects: the utilitarian approach, which 
argues that we seek to maximize the overall good (and do 
trials involving older, non-genetic AD patients as they 
represent the majority of cases), and the deontological 
approach, in which there is an obligation to show good 
will irrespective of outcome (thus include EOAD subjects 
in clinical trials). Th  e utilitarian approach has several 
weaknesses in this context. To be able to establish that 
excluding EOAD subjects would maximize overall good, 
we would need data to support the risks involved when 
including EOAD cases. Th   e risk implies risk for a negative 
trial and risk to the individual. We need to estimate the 
risk for a negative trial imposed by enrolling EOAD 
subjects to establish that we are maximizing overall good. 
Heterogeneity would decrease power by decreasing 
signal-to-noise ratio. However, LOAD is already a 
heterogeneous disorder and overlaps with EOAD in most 
characteristics, and thus it is less likely that heterogeneity 
will increase. In addition, the EOAD subjects would be 
randomly assigned to active and placebo arms, and this 
further decreases the problem with a systemic eﬀ  ect. In 
certain instances (especially in trials of amyloid-based 
therapies), including EOAD subjects and inherently the 
autosomal dominant subset may increase power by 
demonstrating a larger eﬀ   ect in the genotype-speciﬁ  c 
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If this is the case, the utilitarian theory in fact would call 
for including EOAD subjects. We need data to evaluate 
the risk and beneﬁ  t, and enrolling EOAD subjects would 
generate that data. If the protocols address safety issues 
and a priori protocol design includes subgroup analyses, 
we would gather data without basically any risk.
In contrast, the deontological approach would concur 
with the basic moral commitment of non-abandonment 
of these young individuals devastated by AD. If data from 
trials enrolling EOAD subjects suggest that there is an 
increased risk to the trial or to the individual (for 
example, because of more frequent or severe adverse 
reactions), the exclusion would have justiﬁ  cation  and 
further decisions would be more straightforward. We will 
not know the answer until we test the hypothesis, and 
exclusion without justiﬁ  cation because of lack of data is 
ethically unacceptable.
Conclusions
Enrolling EOAD patients in clinical trials has more 
beneﬁ  t than risk involved. Its beneﬁ  ts include potentially 
increasing the power to detect a signal of eﬃ   cacy, 
especially for amyloid-based therapies. Th   e EOAD popu-
lation is unlikely to increase heterogeneity, as the clinical 
phenotypes, imaging, brain metabolism, biomarker, and 
pathological characteristics overlap, and LOAD is already 
a heterogeneous group. Enrolling these patients is ethical 
and generates data that will help estimate risk and beneﬁ  t 
at the level of the clinical trial and the individual. Th  ese 
risk-beneﬁ  t estimates will support informed decisions in 
the future. It is time to stop discriminating against EOAD 
patients in our joint eﬀ  orts to prevent and treat AD.
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